ced pexels 8851256 1

`Cannabinoid Clinical Trials: PTSD and Substance Use Meta-Analysis`

Clinical Takeaway

People with PTSD and co-occurring substance use disorders who use cannabis can still benefit meaningfully from trauma-focused treatments, and cannabis use does not appear to undermine treatment outcomes compared to non-cannabis users. Clinicians should not withhold evidence-based trauma-focused care from patients on the basis of active cannabis use alone.

`Cannabinoid Clinical Trials: PTSD and Substance Use Meta-Analysis`

#6 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.

Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.

Study type: Meta-Analysis, Journal Article, Research Support, N.I.H., Extramural  |  Topic area: Anxiety & PTSD  |  CED Score: 12

Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2

Quality Gate Alerts:

  • Preclinical only

Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total Nย =ย 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (Nย =ย 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.

 |   | 

View on PubMed ↗Full Text ↗DOI ↗